Despite recent advancements in therapy, multiple myeloma (MM) is an incurable disease with the majority of patients relapsing after first-line therapy with immunomodulatory drugs, proteasome inhibitors (PIs), or anti-CD38 antibodies [1, 2]. The gene discussed is CD38; the disease is Miyoshi myopathy.